Table 3.

Subgroup analysis of pooled BCVA means (95% confidence intervals) in ETDRS letters

6 months
Previous anti-VEGF injections (n)	<12 injections 3.83 (0.06–7.59)	12–23 injections 1.45 (−2.24 to 5.13)	≥24 injections −0.05 (−1.60 to 1.50)
Aflibercept injections (n)	<4 injections 2.97 (0.29–5.64)	≥4 injections 0.49 (−1.40 to 2.38)
Dosing	Loading + 2q8 1.42 (−4.71 to 7.56)	Loading + PRN 2.20 (−2.01 to 6.40)	Loading + T&E 0.21 (−3.09 to 3.52)	2q8 0.22 (−0.58 to 1.03)	PRN 3.47 (1.91–5.03)	T&E −1.20 (−4.97 to 2.57)
Study design	Prospective 3.96 (0.72–7.19)	Retrospective 0.25 (−1.26 to 1.75)
12 months
Aflibercept injections (n)	<8 injections 0.53 (−0.53 to 1.59)	≥8 injections 1.05 (−1.48 to 3.57)
Dosing	Loading + 2q8 2.37 (0.34–4.40)	Loading + PRN 13.41 (6.10–20.72)	Loading + T&E −0.73 (−1.32 to −0.14)	2q8 −0.29 (−1.82 to 1.24)	PRN −0.81 (−2.83 to 1.22)
Study design	Prospective 2.79 (−0.12 to 5.70)	Retrospective 0.11 (−0.87 to 1.08)

Note: n represents number, and 2q8 represents bimonthly injections.

Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; PRN, pro re nata; T&E, treat and extend; VEGF, vascular endothelial growth factor.